1 recruiting, 1 terminated, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow Alfred Chung, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Talquetamab, Iberdomide, Dexamethasone - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Alfred Chung, MD | 32 | 2025-07-28 | 2026-03-13 |
| Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) Venetoclax, Dexamethasone, Daratumumab - AL Amyloidosis, Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Withdrawn | Alfred Chung, MD | 2024-01-08 | 2025-03-06 | |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies Pembrolizumab - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 2 | Terminated | Alfred Chung, MD | 3 | 2022-05-03 | 2025-01-15 |
Multiple Myeloma (2) · Amyloidosis (1) · Immunoglobulin Light-chain Amyloidosis (1)
Calcium Dobesilate (2) · Dexamethasone (2) · Biological Assay (1) · Biopsy (1) · In Situ Hybridization (1) · In Situ Hybridization, Fluorescence (1) · daratumumab (1) · iberdomide (1) · pembrolizumab (1) · talquetamab (1) · venetoclax (1)
United States (2)